KEY TAKEAWAYS
- This phase 2 study estimated the per-patient US commercial healthcare costs related to cilta-cel CAR-T therapy for patients with relapsed or refractory multiple myeloma (RRMM).
- The study aimed to determine the cost components and unit costs associated with administering cilta-cel CAR-T therapy, separate from cilta-cel therapy acquisition costs.
- The study determined the cost components using US prescribing data for cilta-cel, openly accessible data, published literature, and clinician input.
- It was found that the costs varied with different proportions of inpatient/outpatient administration, US$158,095 (85%/15%) and US$155,257 (70%/30%).
This study aimed to estimate per-patient US healthcare costs for cilta-cel CAR-T therapy in adult RRMM patients who have received four or more prior lines of treatment, including certain medications, and to separate these costs from cilta-cel therapy acquisition costs.
To determine the costs of administering cilta-cel CAR-T therapy, this study utilized US prescribing information, publicly available data, published literature, and clinician input. The identified cost components comprised apheresis, bridging therapy, conditioning therapy, administration, and post-infusion monitoring for a year follow-up. Additionally, the analysis included AE management costs for cytokine release syndrome, neurologic toxicities, and other AEs grade ≥ 3 occurring in over 5% of patients.
The study found that the average per-patient cost of cilta-cel CAR-T therapy, administered solely in an inpatient setting, was US$160,933 for 12 months, excluding cilta-cel therapy acquisition expenses. Assuming different outpatient-to-outpatient administration ratios, the costs were US$158,095 (85%/15%) and US$155,257 (70%/30%).
The analysis that breaks down the costs of CAR-T therapy offers a comprehensive perspective on CAR-T therapy costs. It can aid healthcare decision-makers in making informed choices about cilta-cel’s usage. However, real-world expenses could vary with the development of better AE prevention and mitigation strategies.
Source: https://pubmed.ncbi.nlm.nih.gov/37014590/
Clinical Trial: https://clinicaltrials.gov/ct2/show/NCT03548207
Jagannath S, Joseph N, Crivera C, Kharat A, Jackson CC, Valluri S, Cost P, Phelps H, Slowik R, Klein T, Smolen L, Yu X, Cohen AD. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. Oncol Ther. 2023 Apr 4. doi: 10.1007/s40487-023-00228-5. Epub ahead of print. PMID: 37014590.
